Encainide

Encainide
Clinical data
Trade names	Enkaid
AHFS/Drugs.com	Micromedex Detailed Consumer Information
MedlinePlus	a605040
ATC code	C01BC08 (WHO) ;
Legal status
Legal status	Withdrawn;
Identifiers
	IUPAC name 4-Methoxy-N-[2-(1-methyl-2-piperidin-1-ylethyl)phenyl]benzamide;
CAS Number	66778-36-7 ;
PubChem CID	48041;
DrugBank	DB01228 ;
ChemSpider	43697 ;
UNII	SY3J0147NB;
KEGG	D07894 ;
ChEBI	CHEBI:4788 ;
ChEMBL	ChEMBL315838 ;
CompTox Dashboard (EPA)	DTXSID0022983 ;
Chemical and physical data
Formula	C22H28N2O2
Molar mass	352.478 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES COc1ccc(C(=O)Nc2ccccc2CCC2CCCCN2C)cc1;
	InChI InChI=1S/C22H28N2O2/c1-24-16-6-5-8-19(24)13-10-17-7-3-4-9-21(17)23-22(25)18-11-14-20(26-2)15-12-18/h3-4,7,9,11-12,14-15,19H,5-6,8,10,13,16H2,1-2H3,(H,23,25) ; Key:PJWPNDMDCLXCOM-UHFFFAOYSA-N ;
	(what is this?) (verify)

Encainide (trade name Enkaid) is a class Ic antiarrhythmic agent. It is no longer used because of its frequent proarrhythmic side effects.^[1]

^ Echt DS, Liebson PR, Mitchell LB, Peters RW, Obias-Manno D, Barker AH, et al. (March 1991). "Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial". The New England Journal of Medicine. 324 (12): 781–8. doi:10.1056/NEJM199103213241201. PMID 1900101.

[1] Echt DS, Liebson PR, Mitchell LB, Peters RW, Obias-Manno D, Barker AH, et al. (March 1991). "Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial". The New England Journal of Medicine. 324 (12): 781–8. doi:10.1056/NEJM199103213241201. PMID 1900101.

[1]